clinical trial · NCT07603557
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase2·not yet recruiting·n = 52
Chronic Immune ThrombocytopeniaAutoimmune Hemolytic AnemiaBMS-986353Fludarabine PhosphateCyclophosphamide
brief summary
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).
started
Aug 31, 2026
primary completion
May 6, 2030
completion
May 6, 2030
last updated
Jul 9, 2026
official title
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol